Q-omics provides the consensus-scored BRI3BP profile across patient tissues and cancer cell-line models. BRI3BP expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, BRI3BP is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, BRI3BP RNA expression shows 19,188 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, BLCA, and UVM as cancer lineages where BRI3BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRI3BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRI3BP survival associations across molecular data types. BRI3BP RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRI3BP RNA expression–survival associations across cancer types. High BRI3BP expression shows unfavorable associations in LIHC, ACC, UVM, MESO, LUAD and KICH. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for BRI3BP RNA expression.
This table summarizes BRI3BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BRI3BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRI3BP shows higher tumor expression in BLCA, STAD, LUAD, LIHC, LUSC and HNSC. The BLCA box plot shows higher BRI3BP RNA expression in tumor versus normal tissue (log2 FC = +2.142, t-test p < 0.001).
This table shows molecular features associated with BRI3BP in patient tissues and cancer cell lines. In patient samples, BRI3BP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BRI3BP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
